Progression of glucose‐lowering diabetes therapy in TECOS

AIMS: TECOS was a randomized, double‐blind, placebo‐controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when added to usual care in patients with type 2 diabetes. We report the use of concomitant diabetes medications and the risk for progression to insulin dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Bethel, M. Angelyn, Engel, Samuel S., Stevens, Susanna R., Lokhnygina, Yuliya, Ding, Jie, Josse, Robert G., Alvarsson, Michael, Hramiak, Irene, Green, Jennifer B., Peterson, Eric D., Holman, Rury R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354756/
https://www.ncbi.nlm.nih.gov/pubmed/30815579
http://dx.doi.org/10.1002/edm2.53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354756/
https://www.ncbi.nlm.nih.gov/pubmed/30815579
http://dx.doi.org/10.1002/edm2.53

Ejemplares similares